Dengue fever in patients under biologics

Journal of Clinical Virology

Volumn 61, Issue 3, 2014, Pages 442-443

  Deligny, Christophe ^a   de Bandt, Michel ^a   Dehlinger, Véronique ^a   Numéric, Patrick ^a   Cabié, André ^a   Lombard, Frederic ^a   Polomat, Katlyne ^a   JeanBaptiste, Georges ^a   Arfi, Serge ^a  

^a University Hospital Pierre Zobda Quitman   (France)

Author keywords

Anti TNF; Biotherapy; Dengue fever; Rheumatoid arthritis; Rituximab

Indexed keywords

RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; VIRUS VECTOR; BIOLOGICAL PRODUCT;

ADULT; AEDES ALBOPICTUS; AGED; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; DENGUE; DISEASE SEVERITY; EUROPE; FEMALE; HUMAN; INFECTION RISK; MALE; PARASITE VECTOR; RHEUMATOID ARTHRITIS; TRAVEL; TROPICS; UNITED STATES; CASE REPORT; COMPLICATION; FRANCE; MIDDLE AGED; PATHOLOGY; RHEUMATIC DISEASES; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL PRODUCTS; DENGUE; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; RHEUMATIC DISEASES; YOUNG ADULT;

EID: 84908596961     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.08.011     Document Type: Article

References (7)

1. Nathan M.B., Dayal-Drager R., Guzman M. Epidemiology, burden of disease and transmission. Dengue guidelines for diagnosis, treatment, prevention and control 2009, 3-24. World Health Organization, Geneva, Switzerland.
2. Institut National de Veille Sanitaire - CIRE Antilles Guyane Le Point épidémiologique. Surveillance de la dengue, Bulletin bimensuel: semaines 2010-44 à 2010-45, Martinique 2010, Available at: http://www.ars.martinique.sante.fr/fileadmin/MARTINIQUE/Votre_Sante/Veille_sanitaire/Les_champs_de_competences/Dengue/PEP/PEP_Martinique/pep_mq_2010/pe_den_mar_10_26.pdf [accessed 21.05.14].
3. Singh J.A., Furst D.E., Bharat A., Curtis J.R., Kavanaugh A.F., Kremer J.M., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease modifying drugs and biologics agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:625-639.
4. Atrasheuskaya A., Petzelbauer P., Fredeking T.M., Ignatyev G. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol 2003, 35:33-42.
5. Perez A.B., Sierra B., Garcia G., Aguirre E., Babel N., Alvarez M., et al. Tumor necrosis factor-alpha, transforming growth factor-β1, and interleukin-10 gene polymorphisms: implication in protection or susceptibility to dengue hemorrhagic fever. Hum Immunol 2010, 71:1135-1140.
6. Fernández-Mestre M.T., Gendzekhadze K., Rivas-Vetencourt P., Layrisse Z. TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens 2004, 64:469-472.
7. Houghton-Triviño N., Salgado D.M., Rodríguez J.A., Bosch I., Castellanos J.E. Levels of soluble ST2 in serum associated with severity of dengue due to tumour necrosis factor alpha stimulation. J Gen Virol 2010, 91:697-706.